PharmaSpotter
SearchVendors
HomeSearchLabKey Software LLC
LabKey Software LLC logo

LabKey Software LLC

"From sample to insight, without the data chaos."

Private
Visit Website

Founded

2005

21 years

Employees

1-50

Annual Revenue

Not Disclosed

(2026)

Products

1

Company Overview

LabKey is a bootstrapped scientific-software vendor headquartered in Seattle, Washington. The work began in 2003 at the Fred Hutchinson Cancer Research Center, where professor Martin McIntosh asked Mark Igra to solve a proteomics data-management problem; Igra was joined by Adam Rauch and Matthew Bellew, all three from Microsoft product teams. Contemporaneous reporting states that "In 2005, the LabKey team spun out the company LabKey Software"; LabKey markets "since 2003" and "20+ years", dating itself from the start of the work at Fred Hutch.

The company has never raised institutional venture capital, growing from six to roughly fifty people on revenue.

The product line spans LabKey Server SDMS (the twenty-year-old foundation, with a free open-source Community Edition), the LIMS Suite — one product sold in five editions, Sample Manager Starter and Professional, LIMS Starter and Enterprise, and Biologics LIMS, with an integrated Electronic Lab Notebook inside it — plus Mining LIMS, LabKey EDC, and Panorama/Skyline mass-spectrometry data management. The platform is open source: NIH-funded improvements accrue to all users, and academic labs adopt the free Community Edition.

Named customers include Fred Hutch, NIH, Takeda, Bristol Myers Squibb, BIOASTER, Biodesix, Candel Therapeutics, and BrainChild Bio, with the vendor claiming 500+ organizations supported. HIPAA, FISMA, PHI flagging, and CFR Part 11 are framed around LabKey Server SDMS and EDC; LabKey publishes no EU Annex 11 mapping, no GAMP 5 categorization, and no pre-validated pharma SKU. A Vanta-hosted Trust Center launched 2026-01-29 publishes a SOC 2 Type 2 engagement with Prescient Assurance, a January 2026 penetration test, and roughly 70 continuously monitored controls, with no completed SOC 2 report and no ISO 27001.

Pharmaceutical Focus

LabKey is not a pharma-specialized vendor: Biotech & Pharma is one of seven marketed verticals alongside Academic Research, Agriculture, Environmental Science, Food & Beverage, Government Research, and Mining & Metals. The commercial product line has been moving toward life sciences since the 2025 LabKey LIMS launch and the Biologics LIMS antibody-discovery product. HIPAA, FISMA, PHI data flagging, and CFR Part 11 are framed around LabKey Server SDMS and LabKey EDC, the tooling of NIH-funded translational and clinical research.

LabKey markets to discovery, translational, bioanalytical, and biobanking labs; it does not market commercial QC batch release. It publishes no EU Annex 11 mapping, no GAMP 5 categorization, no ALCOA+ mapping, no clause-level Part 11 mapping, and no pre-validated pharma SKU, and holds no completed SOC 2 or ISO 27001 attestation (a SOC 2 Type 2 examination is in flight). Validation is a paid add-on of undisclosed price with a published scope: LabKey names the partner (CompliancePath), the Validation Pack contents (URS, Risk Assessment, IQ, OQ), and a validated-release cycle tied to Extended Support Releases with dates and regional rollout waves, run for the LIMS Suite's Sample Manager Professional and LabKey LIMS editions. That written scope does not name Biologics LIMS, while the Biologics LIMS product page sells the same add-on; LabKey resolved the difference by email (2026-08-13): the programme does not cover Biologics LIMS, whose customers perform their own validation or use validated LIMS Enterprise. The named large-pharma customers attach to specific products: Bristol Myers Squibb appears in a published case study on LabKey Server SDMS for CAR T-cell clinical trials and BrainChild Bio on Sample Manager, while no case study names LabKey LIMS — consistent with a product launched in 2025.

Industries Served

PharmaceuticalsBiotechnologyLife SciencesMiningFood & BeverageOther
Financial Overview

LabKey is bootstrapped. GeekWire reported in 2018 that the company had never raised outside funding, growing from six to roughly fifty employees on revenue. One data aggregator reports a single $350K round; no institutional round is evidenced and no investor is named. Revenue is undisclosed.

There is no acquisition or M&A history, no reported layoffs, no litigation, and no reported distress.

Products from LabKey Software LLC

Browse all software products offered by LabKey Software LLC.

LabKey LIMS
LIMS

Cloud-hosted, no-code-configurable LIMS combining sample lineage, freezer inventory, instrument-data ingest, configurable workflow jobs, and an integrated ELN, with published list pricing and bundled implementation.

FDA Part 11
Products & Solutions

LabKey sells the LIMS Suite as one product line in five editions on a single ladder: Sample Manager Starter ($6,540/yr, 5 users), Sample Manager Professional ($13,140/yr, 5 users), LIMS Starter ($34,080/yr, 10 users), LIMS Enterprise ($53,520/yr, 10 users), and Biologics LIMS ($59,400/yr, 10 users). LabKey publishes them as five columns of one feature table — "the features available for each Edition of the LIMS Suite" — under one help tree and one release train, with each edition a strict superset of the one to its left. LIMS Starter adds reporting, analytics and data transformation; LIMS Enterprise adds an SDMS layer (custom SQL, File Watchers, ETLs, external database connections, ODBC/JDBC, SSO) plus enterprise data governance; Biologics LIMS adds entity registration, plate management and media registration, and is the only edition offered on-premise — as a paid add-on rather than an inclusion. The integrated Electronic Lab Notebook is a component inside the suite, not a separate product.

Four separate products sit alongside it. LabKey Server SDMS is the foundation — a customizable scientific data management platform supporting research protocols, analysis tools, data integrations, and compliance requirements, with a free open-source Community Edition. Mining LIMS is a post-2025 vertical variant for metals and mining assay labs. LabKey EDC handles electronic data capture for multisite clinical trials. Panorama provides mass-spectrometry data management tied to the widely used open-source Skyline ecosystem.

The portfolio is tiered by lab type and scale, not by regulatory regime; no pharma or GxP edition exists. Releases are monthly with year.month versioning — an unbroken 26.1 through 26.7 across 2026, and 25.1 through 25.12 before it. Validated customers upgrade instead on a slower Extended Support Release line.

Partnerships & Technology

One named delivery partner, disclosed on a documentation page rather than a partners page: CompliancePath performs software validation for Sample Manager Professional and LabKey LIMS as a paid add-on, maintaining a Validation Pack (URS, Risk Assessment, IQ, OQ) that is refreshed for each Extended Support Release and delivered to LabKey and customers on a published eleven-week cycle. No reseller, systems-integrator, or implementation-partner network is disclosed; implementation is bundled into the subscription and delivered in-house. Technology integrations: Tableau, Power BI, and RStudio connectors for analysis; file watchers and transformation scripts for instrument connectivity across arbitrary output formats; LDAP, CAS, SAML, and Duo two-factor for authentication; and, as of release 26.7, an MCP server exposing LabKey data and server operations to desktop AI agents.

Institutional relationships are research-side: the Fred Hutchinson Cancer Research Center origin, sustained NIH-funded work, and Panorama, where LabKey's software underpins the open-source Skyline mass-spectrometry ecosystem.

Support & Services

Implementation and onboarding, training, and ongoing support are bundled into every plan — "dedicated support from day one, not just a help doc" and "we work with your team until they're confident." Validation support for regulated labs is the one separately priced add-on; its deliverables are published — CompliancePath, a Validation Pack of URS, Risk Assessment, IQ and OQ, refreshed per Extended Support Release, on a documented eleven-week cycle with dated regional rollout waves — while the price band is not; PQ is purchased as Phase 2 of the pack or performed by the customer (LabKey, by email 2026-08-13).

Public documentation at labkey.org is ungated: the LIMS Suite Help tree at /limshelp covers sample, storage, assay, workflow, ELN, administration, and API topics, plus the edition comparison, the LIMS Enterprise capability list, the release notes, and the Validation Schedule. LabKey's marketing validation explainer at labkey.com/lims-validation does not mention CompliancePath, the Validation Pack, or the ESR cycle, and the LabKey LIMS product page does not contain the string "Part 11"; the compliance and validation material lives on labkey.org.

Undisclosed: support hours and severity SLAs, regional coverage outside the US, customer-success program structure, user community events, and certification programs.

Validation
Credibility & Recognition

LabKey originated as a Fred Hutchinson Cancer Research Center spinout, has a substantial NIH and US federal research footprint (reflected in FISMA and HIPAA support), and its software underpins the Panorama/Skyline mass-spectrometry ecosystem used across the proteomics community. Named customers include Fred Hutch, NIH, Takeda, Bristol Myers Squibb, BIOASTER, Biodesix, Candel Therapeutics, and BrainChild Bio, with 500+ organizations claimed over 20+ years.

There is no Gartner, Forrester, Frost & Sullivan, or IDC recognition. Third-party review presence: a G2 seller page showing 4.6/5 across 10 reviews, every one of them against LabKey Server rather than any LIMS product and the most recent visible ones dating from 2023, with no Capterra or Gartner Peer Insights listing.

LabKey runs a Vanta-hosted Trust Center at trust.labkey.com, live since 2026-01-29, publishing a SOC 2 Type 2 audit letter of intent with Prescient Assurance, a Vanta SOC 2 Type II engagement letter, a January 2026 web penetration test and attestation letter available on request, roughly 70 continuously monitored controls, and a named subprocessor list. There is no completed SOC 2 report and no ISO 27001 or ISO 9001 claim.

Market Presence

Published list pricing puts LabKey LIMS at $34,080-$53,520 per year for 10 users, with implementation bundled into the subscription and documentation ungated.

Marketing operation is active and content-led: an extensive resource library (what-is-a-LIMS explainers, LIMS validation guides, implementation best practices, competitive comparison pieces), a HubSpot-hosted product tour and FAQ collateral, and webinars.

Market position by segment: long-established in academic, government, and translational research; emerging in biotech R&D and biologics discovery; largely absent from commercial GMP pharma manufacturing.

Company Details

Headquarters

Seattle, Washington, United States

Founded

2005 (21 years in business)

Company Size

1-50 employees

Type

Private

Owned by Not applicable - independent, founder-owned company

Annual Revenue

Not Disclosed (2026)

FDA-Compliant Solutions
Community Contributed
No Sponsored Rankings
Updated Weekly

PharmaSpotter

Comprehensive directory of pharmaceutical software solutions. QMS, LIMS, MES, analytics, and compliance tools for FDA-regulated manufacturing environments.

22 Solution Categories•Curated Data

Software Categories

  • Quality Management Systems
  • Manufacturing Execution Systems
  • Lab Information Management
  • Electronic Batch Records
  • CAPA & Deviation Management
  • Change Control
  • View All Categories →

Resources

  • RFP Template
  • Vendor Scorecard
  • Compliance Guide
  • Implementation Timeline
  • Contribute Data
© 2025 PharmaSpotter. All rights reserved.
Curated pharmaceutical software directory for FDA-regulated manufacturing environments
AboutContactContribute•Privacy PolicyTermsDisclaimer